Corporate Update – Akeso Inc. (9926.HK)
Akeso Inc. (HK: 9926) advanced 1.53 % on Thursday, 22 Oct 2026, trading at HK $83.90 as of 11:25 AM CET. The stock remains a high‑volume instrument, with 926.9 million shares outstanding and a market capitalization of HK $86 billion. In the last 24 hours, approximately HK $707.8 million of shares changed hands, a figure that sits comfortably below the 24‑hour average for the sector.
Trading Context
- Current 24‑hour range: 1.53 % gain against a 3.23 % decline since the end of the previous month.
- Moving averages: The 200‑day simple moving average sits at HK $107.79, underscoring a modest bullish bias relative to the longer‑term trend.
- Historical extremes: The 52‑week high of HK $156 was reached on 17 April 2026; the low of HK $80.20 appeared on 22 June 2026, positioning the current price within a historically favorable band for a company with a robust pipeline.
Strategic Milestone – Phase II/III Trial Announcement
Akeso announced that its lead bispecific antibody, ivonescimab, will enter a Phase II/III registration‑enabling study (EA2251) in biliary‑tract cancer. The trial will be executed in collaboration with Summit Therapeutics and the ECOG‑ACRIN Cancer Research Group. Key elements include:
| Item | Detail |
|---|---|
| Study Design | IVonescimab + standard chemotherapy vs. established immunotherapy‑based regimens |
| Primary Endpoint | Overall survival |
| U.S. Activation | Q4 2026 |
| Rationale | Positive interim data from HARMONi‑GI1 demonstrated a clinically meaningful survival advantage for ivonescimab + chemotherapy over durvalumab + chemotherapy. |
| Strategic Impact | Positions ivonescimab within a disease landscape that offers limited first‑line options, potentially accelerating global development and market access. |
The collaboration signals Akeso’s intent to expand the therapeutic footprint of ivonescimab beyond its current indications. The partnership with Summit and ECOG‑ACRIN not only augments trial infrastructure but also leverages a well‑established clinical network, thereby enhancing the probability of regulatory acceptance.
Market Sentiment & Comparable Performance
In the past 24 hours, Akeso’s peers have displayed varied activity:
| Stock | Ticker | 24‑hr Move | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Tbea | 600089.SS | 0 % | CNY 17.30 | CNY 86.7 bn | 16.69 |
| Ieit | 000977.SZ | 0 % | CNY 57.02 | CNY 84.6 bn | 18.83 |
| Lingyi Itech Guangdong‑H | 002600.SZ | 0 % | CNY 10.92 | CNY 84.5 bn | 37.84 |
| Sichuan Chuantou Energy | 600674.SS | 0 % | CNY 17.25 | CNY 84.5 bn | 16.91 |
| Cspc Pharmaceutical Lt | 1093.HK | –2.47 % | HKD 8.36 | HKD 101.8 bn | 11.38 |
While most peers have remained flat, Akeso’s upward movement aligns with the positive momentum generated by its latest clinical announcement. The modest 1.53 % gain, against a backdrop of sector stability, suggests that investors are acknowledging the strategic value of the EA2251 study without overreacting to short‑term volatility.
Forward Outlook
With the Phase II/III study on the horizon, Akeso is poised to strengthen its commercial pipeline. The combination of a solid market cap, healthy liquidity, and a clear regulatory path for ivonescimab positions the company favorably for sustained shareholder value creation. Investors should monitor the trial’s enrollment metrics and interim efficacy data, which are expected to surface in Q1 2027.
